Background-Desensitization and downregulation of myocardial -adrenergic receptors (ARs) are initiated by the increase in AR kinase 1 (ARK1) levels. By interacting with ARK1 through the phosphoinositide kinase (PIK) domain, phosphoinositide 3-kinase (PI3K) is targeted to agonist-stimulated ARs, where it regulates endocytosis. We tested the hypothesis that inhibition of receptor-targeted PI3K activity would alter receptor trafficking and ameliorate AR signaling, ultimately improving contractility of failing cardiomyocytes. Methods and Results-To competitively displace PI3K from ARK1, we generated mice with cardiac-specific overexpression of the PIK domain. Seven-day isoproterenol administration in wild-type mice induced desensitization of ARs and their redistribution from the plasma membrane to early and late endosomes. In contrast, transgenic PIK overexpression prevented the redistribution of ARs away from the plasma membrane and preserved their responsiveness to agonist. We further tested whether PIK overexpression could normalize already established AR abnormalities and ameliorate contractile dysfunction in a large animal model of heart failure induced by rapid ventricular pacing in pigs. Failing porcine hearts showed increased ARK1-associated PI3K activity and marked desensitization and redistribution of ARs to endosomal compartments. Importantly, adenoviral gene transfer of the PIK domain in failing pig myocytes resulted in reduced receptor-localized PI3K activity and restored to nearly normal agonist-stimulated cardiomyocyte contractility. Conclusions-These data indicate that the heart failure state is associated with a maladaptive redistribution of ARs away from the plasma membrane that can be counteracted through a strategy that targets the ARK1/PI3K complex. Key Words: catecholamines Ⅲ gene therapy Ⅲ heart failure Ⅲ receptors, adrenergic, beta A bnormalities in the -adrenergic receptor (AR) signaling system such as a reduction in the number of ligand-accessible ARs (downregulation) and diminished response to catecholamine stimulation of remaining receptors (desensitization) are hallmarks of heart failure. 1,2 However, whether changes in AR signaling represent an adaptive and protective process, as some postulate, 3 or whether AR dysregulation actually promotes deterioration of cardiac function 4 is still controversial. 3 Results from our previous studies suggest that chronic AR dysfunction in the failing heart is maladaptive and contributes to the deterioration in cardiac function. 4 Indeed, a consistent and prominent feature of -blocker therapy in heart failure is the reversal of AR dysfunction. 5,6 Considerable evidence supports the concept that the chronic increase in circulating catecholamine levels is largely responsible for the AR abnormalities found in failing hearts. 4 Agonist-induced receptor dysfunction begins with AR phosphorylation by ARK1, followed by -arrestin binding that sterically interdicts further G-protein coupling and initiates the process of receptor intern...